Related Experiment Videos

Dapagliflozin: an emerging treatment option in type 2 diabetes

Mark Kipnes1

  • 1DGD Research Associates, Inc., a Cetero Research Company, 5107 Medical Drive, San Antonio, TX 78229, USA. mkipnes@dgdresearch.com

Expert Opinion on Investigational Drugs
|February 27, 2009
PubMed

Insights

Dapagliflozin, a new agent targeting sodium-glucose co-transporter 2 (SGLT2), effectively lowers blood glucose in type 2 diabetes. This approach inhibits kidney glucose reabsorption, offering a promising strategy to manage hyperglycemia and its complications.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Global type 2 diabetes mellitus incidence is rising, with hyperglycemia worsening complications and disease progression.
  • Novel therapeutic agents are crucial for slowing diabetes progression and reducing associated complications.

Purpose of the Study:

  • To review the role of dapagliflozin as an emerging treatment option for type 2 diabetes mellitus.
  • To explore the mechanism of action and clinical efficacy of SGLT2 inhibition.

Main Methods:

  • Preclinical studies assessed dapagliflozin's potency, selectivity, pharmacokinetics, and elimination.
  • Clinical trials evaluated dapagliflozin's effects on glycemic parameters and urinary glucose excretion in type 2 diabetes patients.

Main Results:

  • Dapagliflozin demonstrated potent and selective inhibition of sodium-glucose co-transporter 2 (SGLT2).
  • Pharmacokinetic studies showed linear absorption and primarily urinary excretion.
  • Clinical trials confirmed dapagliflozin induces glucosuria and improves glycemic control in type 2 diabetes.

Conclusions:

  • Inhibition of SGLT2 represents a novel and promising therapeutic approach for type 2 diabetes mellitus.
  • Dapagliflozin's efficacy in improving glycemic parameters positions it as a significant emerging treatment option.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...